NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Nonalcoholic fatty liver disease (NAFLD) is becoming the leading cause of liver disease worldwide, and the prevalence is still increasing, especially during the developmental age (1-3). NAFLD is defined in the presence of increased hepatic fat content not explained by at risk alcohol intake, and is epidemiologically associated with obesity, insulin resistance and metabolic disorders.
7
2019-07-16(万方平台首次上网日期,不代表论文的发表时间)
共3页
484-486